RS20050484A - Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat - Google Patents

Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat

Info

Publication number
RS20050484A
RS20050484A YUP-2005/0484A YUP20050484A RS20050484A RS 20050484 A RS20050484 A RS 20050484A YU P20050484 A YUP20050484 A YU P20050484A RS 20050484 A RS20050484 A RS 20050484A
Authority
RS
Serbia
Prior art keywords
inhalation
powder
inhalation powder
salmeterol xinafoate
tiotropium
Prior art date
Application number
YUP-2005/0484A
Other languages
English (en)
Serbian (sr)
Inventor
Hagen Graebner
Heimel Mareke Hartig
Peter Sieger
Rainer Soyka
Michael Trunk
Michael Walz
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20050484(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg., filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.,
Publication of RS20050484A publication Critical patent/RS20050484A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
YUP-2005/0484A 2002-12-20 2003-12-04 Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat RS20050484A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20
PCT/EP2003/013691 WO2004058233A1 (de) 2002-12-20 2003-12-04 Pulverförmige arzneimittel zur inhalation enthaltend ein tiotropiumsalz und salmeterolxinafoat

Publications (1)

Publication Number Publication Date
RS20050484A true RS20050484A (sr) 2007-11-15

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0484A RS20050484A (sr) 2002-12-20 2003-12-04 Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat

Country Status (21)

Country Link
EP (1) EP1581198A1 (de)
JP (1) JP2006516135A (de)
KR (1) KR20050086930A (de)
CN (1) CN1728988B (de)
AU (1) AU2003288226B2 (de)
BR (1) BR0317443A (de)
CA (1) CA2510779A1 (de)
DE (1) DE10351663A1 (de)
EA (1) EA010588B1 (de)
EC (1) ECSP055855A (de)
FR (1) FR2848849B1 (de)
HR (1) HRP20050570A2 (de)
IT (1) ITMI20032473A1 (de)
MX (1) MXPA05006519A (de)
NO (1) NO20053548L (de)
NZ (1) NZ541303A (de)
PL (1) PL376231A1 (de)
RS (1) RS20050484A (de)
UA (1) UA83813C2 (de)
WO (1) WO2004058233A1 (de)
ZA (1) ZA200503692B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
CA2617897A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
KR101395881B1 (ko) * 2005-12-19 2014-05-21 시코르, 인크. 브롬화 티오트로피움의 신규한 형태 및 이의 제조 방법
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
DE102007036411A1 (de) 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
UY31235A1 (es) * 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (de) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP3880251B1 (de) * 2018-11-13 2025-04-09 Cocrystal Pharma, Inc. Formulierungen von influenzatherapeutika

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
DE10104367A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
WO2003013633A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Inhalation device with a pharmaceutical composition
EP1429768B1 (de) * 2001-09-14 2016-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Neue arzneimittel zur inhalation

Also Published As

Publication number Publication date
AU2003288226B2 (en) 2010-01-07
NO20053548L (no) 2005-09-02
MXPA05006519A (es) 2005-08-26
PL376231A1 (en) 2005-12-27
WO2004058233A1 (de) 2004-07-15
CN1728988B (zh) 2010-04-28
ZA200503692B (en) 2006-10-25
HRP20050570A2 (en) 2006-07-31
JP2006516135A (ja) 2006-06-22
BR0317443A (pt) 2005-11-16
DE10351663A1 (de) 2004-07-01
FR2848849A1 (fr) 2004-06-25
CA2510779A1 (en) 2004-07-15
CN1728988A (zh) 2006-02-01
UA83813C2 (ru) 2008-08-26
ECSP055855A (es) 2005-11-22
EA200500902A1 (ru) 2006-02-24
NZ541303A (en) 2008-11-28
EA010588B1 (ru) 2008-10-30
ITMI20032473A1 (it) 2004-06-21
EP1581198A1 (de) 2005-10-05
KR20050086930A (ko) 2005-08-30
AU2003288226A1 (en) 2004-07-22
FR2848849B1 (fr) 2007-01-05

Similar Documents

Publication Publication Date Title
AU757008B2 (en) Novel tiotropium-containing inhalation powder
AU2003288226B2 (en) Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate
US20040152720A1 (en) Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
US8197845B2 (en) Encapsulated tiotropium containing powder formulation for inhalation
US7462367B2 (en) Anticholinergic powder formulations for inhalation
JP4331619B2 (ja) 臭化チオトロピウムの結晶性微粒子
RS51599B (sr) Novi kristalni anhidrat sa antiholinergijskim dejstvom
RS20050400A (sr) Nove formulacije praha za inhaliranje koje sadrže tiotropijum
MXPA04009583A (es) Nuevas formulaciones en polvo adecuadas para inhalacion.
CA2531832C (en) Powdery formulations for inhalation, containing a novel anticholinergic agent
WO2006076222A2 (en) Pharmaceutical formulations
HK40037203A (en) Novel carrier particles for dry powder formulations for inhalation
NZ540844A (en) Pulverulent formulation for inhalation containing tiotropium